Long-Term Safety of OROS Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder

Abstract

OROS methylphenidate, in the flexible dosage range from 36 to 108 mg/d, was well tolerated for up to 1 year in adults with ADHD.

Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): An open-label prospective study of time in treatment, dose, side-effects and comorbidity

“…Reasons to terminate medication included side-effects such as heart palpitations, mood instability, nausea, agitation and anxiety. This is consistent with other studies on safety and tolerability (Adler et al, 2011;Bejerot et al, 2010;Buitelaar et al, 2011). Most patients experienced mild side-effects.…”

“…Medication dosage seemed adequate, and in line with other studies on adults (Wender et al, 2011;Adler et al, 2011;Marchant et al, 2010). As reported in a study of a younger patient population (aged 9-21 years) (Powell et al, 2011) we found variations in dosages across time and individuals, although patients with the highest dosages had the best response.…”

“…Few long-term prospective studies have been conducted on adult ADHD patients in a practical clinical setting (Powell et al, 2011;Weiss et al, 2010;Bejerot et al, 2010;Adler et al, 2011). A naturalistic two-year follow-up study (Bejerot et al, 2010) examined adherence to stimulant treatment, side-effects and medication discontinuation in adult ADHD patients.…”

“…Limitations include selection bias due to patients entering and leaving at different stages of treatment, lack of reports on side-effects, and problems with defining common endpoints. A one-year openlabel prospective study (Adler et al, 2011) evaluated long-term safety of osmotic release formulation of MPH, and found that a flexible dosage-regime was well tolerated, but only 44% completed 12 months of treatment. The most prevalent sideeffects were decreased appetite, headache, and insomnia.…”

Personality Disorder in Adult Attention-Deficit/Hyperactivity Disorder

“…Adler et al (2009) reported that 60% of subjects entering the longterm portion of their study with dexmethylphenidate completed the study, whereas Adler et al (2011) reported that 57% of subjects entering the long-term portion of their study with OROS MPH completed 6 months of the study. Weisler et al (2009) reported that 55% of subjects entering the long-term portion of their study with lisdexamfetamine completed 12 months of the study.…”